What is the likely diagnosis and recommended management for a patient with three weeks of left-hand swelling that improves with cold exposure and massage, associated axillary pain, normal complete blood count and comprehensive metabolic panel, negative rheumatoid factor, and a homogeneous antinuclear antibody titer of 1:160 with no evidence of venous thrombosis?

Likely Diagnosis and Management

This patient should be urgently referred to a rheumatologist within 6 weeks for evaluation of early undifferentiated inflammatory arthritis, given the three-week duration of joint swelling with a positive ANA, even with negative rheumatoid factor. 1

Clinical Assessment

The presentation of unilateral hand swelling for three weeks with associated axillary pain, positive ANA (1:160 homogeneous pattern), and negative rheumatoid factor suggests early undifferentiated inflammatory arthritis that may evolve into a defined connective tissue disease. 1

Key Diagnostic Considerations:

• Early inflammatory arthritis: The three-week duration of joint swelling with pain meets criteria for urgent rheumatology referral, as patients presenting with any joint swelling associated with pain or stiffness should be seen by a rheumatologist within 6 weeks of symptom onset. 1

• ANA positivity significance: A homogeneous ANA pattern at 1:160 titer, while relatively low, is clinically relevant in the context of inflammatory symptoms and warrants further autoimmune workup. 2 Patients seropositive for ANA are more likely to have autoimmune-related disease and may benefit from immunomodulatory therapy even without meeting strict classification criteria. 3

• Negative RF does not exclude inflammatory arthritis: The absence of rheumatoid factor does not rule out early rheumatoid arthritis or other inflammatory conditions, as RF can be negative in early disease. 1

Immediate Management Steps

1. Urgent Rheumatology Referral

• Refer immediately for specialist evaluation, as this patient has had symptoms for three weeks (within the critical 6-week window for optimal outcomes). 1
• Clinical examination by a rheumatologist is the method of choice for detecting arthritis, which may be confirmed by ultrasonography if clinical findings are equivocal. 1

2. Additional Laboratory Testing Required

The following tests should be obtained to complete the workup for early arthritis and exclude other diagnoses: 1

• Anti-CCP antibodies (anti-cyclic citrullinated peptide): Consider testing given negative RF, as anti-CCP can be positive in seronegative RA and helps predict erosive disease. 1
• ESR and CRP: Acute phase reactants are essential for assessing inflammatory activity and predicting persistent/erosive disease. 1
• Complete autoimmune panel: Given positive ANA, obtain anti-dsDNA, anti-Ro (SS-A), anti-La (SS-B), complement levels (C3, C4) to evaluate for systemic lupus erythematosus or Sjögren's syndrome. 2, 3

3. Imaging

• Ultrasound with power Doppler of the affected hand and axilla should be performed to confirm synovitis, assess for joint effusion, and evaluate the axillary region for lymphadenopathy or other pathology. 1
• Baseline radiographs of hands to assess for early erosive changes. 1

Symptomatic Management Pending Rheumatology Evaluation

Short-term Pharmacologic Options:

• NSAIDs: Naproxen 500 mg twice daily or meloxicam 7.5-15 mg daily for 4-6 weeks after evaluating gastrointestinal, renal, and cardiovascular risks. 1 Use at minimum effective dose for shortest duration possible. 1

• Low-dose corticosteroids: If NSAIDs are ineffective or contraindicated, consider prednisone 10-20 mg daily for 2-4 weeks as temporary adjunctive treatment. 1 Systemic glucocorticoids should be used at the lowest necessary dose for less than 6 months due to cumulative side effects. 1

• Continue cold therapy and massage: The patient's symptomatic improvement with cold application and massage can continue as adjunctive non-pharmacological measures. 4

Critical Pitfalls to Avoid

• Do not delay referral waiting for additional serologic results—the three-week symptom duration is already approaching the critical 6-week window where early DMARD initiation provides optimal outcomes. 1

• Do not dismiss the diagnosis based on negative rheumatoid factor alone—patients at risk of persistent arthritis should be started on DMARDs early (ideally within 3 months), even if they do not fulfill classification criteria for a specific inflammatory rheumatologic disease. 1

• Do not attribute symptoms solely to non-inflammatory causes (such as lymphedema or venous insufficiency) without rheumatologic evaluation, given the positive ANA and inflammatory presentation. 1

Expected Rheumatology Workup

Once evaluated by rheumatology, the specialist will assess risk factors for persistent and erosive disease including: 1

• Number of swollen and tender joints
• Acute phase reactants (ESR, CRP)
• Complete autoantibody profile
• Imaging findings (ultrasound, radiographs)

If classified as at-risk for persistent arthritis, methotrexate should be initiated as the anchor DMARD, unless contraindicated, with the goal of achieving clinical remission. 1 Disease activity monitoring should occur at 1-3 month intervals until treatment target is reached. 1